We wish to validate a DNA methylation prognostic classifier that can differentiate between high-risk and low-risk neuroblastoma patients. To select candidate markers, MBD2-sequencing will be performed on primary tumor samples, combined with an integrative analysis of earlier research results. Using MSP, these markers will then be validated in independent patient sets and on patient bone marrow and serum samples.